Gulfo Adele M. 4

What Happened
Gulfo Adele, a director of Tyra Biosciences (TYRA), was granted an option award covering 13,160 shares on May 28, 2026. The transaction is reported as an award/acquisition with a reported price of $0.00 (derivative grant), meaning this was a stock-option or similar equity award, not an open-market purchase or sale.

Key Details

• Transaction date: May 28, 2026; Form filed June 1, 2026.
• Transaction type: Award/Grant (derivative) of 13,160 shares; reported acquisition price $0.00.
• Vesting: 1/12th of the total option vests monthly beginning May 28, 2026. If the next annual stockholder meeting occurs before the one-year anniversary, any remaining unvested portion will vest on that meeting date, subject to continued service. (From filing footnote.)
• Shares owned after transaction: Not specified in this filing.
• Filing timeliness: Form filed four days after the grant; filing does not indicate a late-report flag in the provided data.

Context
This was an equity compensation grant under Tyra’s Non-Employee Director Compensation Program for a board member. Such grants are routine for directors and vest over time as described; they do not represent an immediate cash purchase or sale and should be viewed as compensation rather than a direct market sentiment signal.